uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. USO
2. META
3. NVDA
4. SPY
5. DCOY
6. MSFT
7. VKTX
8. PRGS
9. ONON
10. CMPX

Go back to uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy
UNIQURE (NASDAQ: QURE) Delayed: 45.28 +0.97 (2.19%)
Previous Close $44.31    52 Week High $22.79 
Open $44.50    52 Week Low $6.63 
Day High $45.80    P/E N/A 
Day Low $44.47    EPS $0.00 
Volume 1,145,200